Inventor · disambiguated record
Glenn E. Dale
Also filed as: DALE GLENN · DALE GLENN E
15 granted patents·14 pending applications·15 citations·filing 2004–2025
89Inventor score
Top patents by PatentIndex Score
29 records- 0189US11207305B2Antibiotic combination therapiesBioVersys AG·Filed 2020·Granted Dec 28, 2021·2 cites·20 claims
- 0288US11766425B2Antibiotic combination therapiesBioVersys AG·Filed 2021·Granted Sep 26, 2023·1 cites·21 claims
- 0386US12403133B2Rifabutin treatment methods, uses, and compositionsBioVersys AG·Filed 2024·Granted Sep 2, 2025·0 cites·20 claims
- 0484US12257241B2Rifabutin treatment methods, uses, and compositionsBioVersys AG·Filed 2023·Granted Mar 25, 2025·0 cites·24 claims
- 0582US9403818B2Antimicrobial 4-oxoquinolizinesHEIM JUTTA·Filed 2012·Granted Aug 2, 2016·5 cites·6 claims
- 0682US2025360115A1Rifabutin treatment methods, uses, and compositionsBioVersys AG·Filed 2025·Application pending·0 cites
- 0780US11833139B2Rifabutin treatment methods, uses, and compositionsBioVersys AG·Filed 2022·Granted Dec 5, 2023·0 cites·16 claims
- 0879US11903934B2Rifabutin treatment methods, uses, and compositionsBioVersys AG·Filed 2022·Granted Feb 20, 2024·0 cites·10 claims
- 0978US2025281469A1Rifabutin treatment methods, uses, and compositionsBioVersys AG·Filed 2025·Application pending·0 cites
- 1076US9814754B2Combinations with a backbone-cyclized peptidePOLYPHOR AG·Filed 2013·Granted Nov 14, 2017·3 cites·24 claims
- 1176US9775877B2Combinations with a backbone-cyclized peptidePOLYPHOR AG·Filed 2013·Granted Oct 3, 2017·3 cites·10 claims
- 1275US10517865B22-pyridone antimicrobial compositionsEMERGENT PRODUCT DEV GAITHERSBURG INC·Filed 2018·Granted Dec 31, 2019·1 cites·6 claims
- 1372US11351158B2Rifabutin treatment methods, uses, and compositionsBioVersys AG·Filed 2020·Granted Jun 7, 2022·0 cites·21 claims
- 1471US11344537B2Rifabutin treatment methods, uses, and compositionsBioVersys AG·Filed 2020·Granted May 31, 2022·0 cites·16 claims
- 1570US12370184B2Antibiotic combination therapiesBioVersys AG·Filed 2023·Granted Jul 29, 2025·0 cites·20 claims
- 1664US2019105367A1Antimicrobial 4-oxoquinolizinesEMERGENT PRODUCT DEV GAITHERSBURG INC·Filed 2018·Application pending·0 cites
- 1762US2025213575A18-heterocyclic-3-(phenylsulfonyl)-[1,2,3]triazolo[1,5a]quinazolin-5(4h)-one derivatives as anti-bacterialsBioVersys AG·Filed 2023·Application pending·0 cites
- 1862US2025376472A13-(phenylsulfonyl)-[1,2,3]triazolo[1,5a]quinazolin-5(4h)-one derivativesBioVersys AG·Filed 2023·Application pending·0 cites
- 1961US10155021B2Antimicrobial 4-oxoquinolizinesEMERGENT PRODUCT DEV GAITHERSBURG INC·Filed 2016·Granted Dec 18, 2018·0 cites·14 claims
- 2061US2023364065A1Antibiotic combination therapiesBioVersys AG·Filed 2022·Application pending·0 cites
- 2161US2025101039A1Rifamycin derivatives for the treatment of diseasesBioVersys AG·Filed 2023·Application pending·0 cites
- 2260US2025051356A1Rifabutin analogs for the treatment of diseaseBioVersys AG·Filed 2022·Application pending·0 cites
- 2360US2025235434A1Rifabutin analogs for the treatment of diseaseBioVersys AG·Filed 2023·Application pending·0 cites
- 2454US2017209437A12-pyridone antimicrobial compositionsEMERGENT PRODUCT DEV GAITHERSBURG INC·Filed 2017·Application pending·0 cites
- 2546US2010324030A15-Quinoline derivatives having an anti-bacterial activityMORPHOCHEM AG FUR KOMBINATORISCHE CHEMIE·Filed 2008·Application pending·0 cites
- 2645US2025360114A1Intravenous rifabutin formulation and methods of makingBioVersys AG·Filed 2025·Application pending·0 cites
- 2737US2006046978A1Novel compounds that inhibit dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/or angiotensin converting enzyme (ACE)MORPHOCHEM AG·Filed 2004·Application pending·0 cites
- 2833US11629171B2Beta-hairpin peptidomimeticsPOLYPHOR AG·Filed 2018·Granted Apr 18, 2023·0 cites·3 claims
- 2933US2007244103A1Novel Compounds Having an Anti-Bacterial ActivityMORPHOCHEM AG KOMB CHEMIE·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Glenn E. Dale files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →